^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CCNE1 amplification

    i
    Other names: CCNE1, CCNE, Cyclin E1
    Entrez ID:
    898
    Related biomarkers:
    Expression
    Mutation
    Others
    Apply
    Palbociclib and Pembrolizumab in Central Nervous System Metastases (NCT02896335)
    Phase 2
    Massachusetts General Hospital
    Recruiting
    Last update posted :
    11/21/2024
    Initiation :
    02/02/2017
    Primary completion :
    09/01/2025
    Completion :
    09/01/2026
    CDKN2A • CCND1 • CCNE1 • CDK4 • CDK6 • CCND2 • CCND3
    |
    CCNE1 amplification • CCND1 amplification • CDK4 amplification
    |
    Keytruda (pembrolizumab) • Ibrance (palbociclib)
    RP-6306 in Patients With Advanced Cancer (NCT05605509)
    Phase 2
    Canadian Cancer Trials Group
    Recruiting
    Last update posted :
    06/12/2024
    Initiation :
    05/24/2023
    Primary completion :
    12/01/2024
    Completion :
    06/01/2025
    HER-2 • KRAS • TP53 • CCNE1 • UGT1A1
    |
    TP53 mutation • KRAS mutation • HER-2 amplification • RAS mutation • CCNE1 amplification • UGT1A1*28 • UGT1A1*1*1
    |
    Herceptin (trastuzumab) • gemcitabine • 5-fluorouracil • irinotecan • leucovorin calcium • lunresertib (Debio2513)
    Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer (INX-315-01) (NCT05735080)
    Phase 1/2
    Incyclix Bio
    Recruiting
    Last update posted :
    05/22/2024
    Initiation :
    03/28/2023
    Primary completion :
    12/01/2025
    Completion :
    06/01/2026
    HER-2 • ER • CCNE1
    |
    HER-2 negative • CCNE1 amplification
    |
    INX-315
    (VELA) Study of BLU-222 in Advanced Solid Tumors (NCT05252416)
    Phase 1/2
    Blueprint Medicines Corporation
    Recruiting
    Last update posted :
    04/23/2024
    Initiation :
    04/07/2022
    Primary completion :
    11/30/2025
    Completion :
    09/30/2026
    HER-2 • CCNE1
    |
    HER-2 negative • CCNE1 amplification
    |
    carboplatin • Kisqali (ribociclib) • fulvestrant • cirtociclib (BLU-222)
    Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer (BISCAY) (NCT02546661)
    Phase 1
    AstraZeneca
    Active, not recruiting
    Last update posted :
    03/12/2024
    Initiation :
    10/03/2016
    Primary completion :
    03/18/2020
    Completion :
    06/28/2024
    HRD • CDKN2A • RB1 • FGFR • CD8 • CCNE1 • MYCN • IFNG • IL6 • IL2 • IL10 • MYCL
    |
    PD-L1 expression • FGFR3 mutation • CDKN2A deletion • CCNE1 amplification • CDKN2A mutation • FGFR fusion • RB1 deletion • MYCL amplification
    |
    Lynparza (olaparib) • Imfinzi (durvalumab) • Koselugo (selumetinib) • adavosertib (AZD1775) • fexagratinib (ABSK091) • vistusertib (AZD2014) • danvatirsen (AZD9150)
    Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study (NCT04197713)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    11/08/2023
    Initiation :
    06/30/2020
    Primary completion :
    02/22/2023
    Completion :
    09/21/2024
    BRCA1 • BRCA2 • FANCA • BRIP1 • CD4
    |
    BRCA2 mutation • BRCA1 mutation • CCNE1 amplification • BRIP1 mutation • FANCA mutation
    |
    Lynparza (olaparib) • adavosertib (AZD1775)
    AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification (NCT03253679)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    10/17/2023
    Initiation :
    01/16/2019
    Primary completion :
    10/31/2022
    Completion :
    10/31/2022
    CCNE1
    |
    CCNE1 amplification
    |
    adavosertib (AZD1775)
    M6620 (VX-970) in Selected Solid Tumors (NCT03718091)
    Phase 2
    Massachusetts General Hospital
    Completed
    Last update posted :
    07/07/2023
    Initiation :
    01/08/2019
    Primary completion :
    06/01/2020
    Completion :
    07/08/2020
    BRCA1 • BRCA2 • MYC • ATM • ARID1A • CCNE1 • CDK12 • FBXW7 • ATRX • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCE • FANCC
    |
    BRCA2 mutation • BRCA1 mutation • ATM mutation • ARID1A mutation • MYC amplification • CCNE1 amplification • CDK12 mutation • ATRX mutation • CHEK2 mutation • FBXW7 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • FANCF mutation • MRE11A mutation • NBN mutation • FANCM mutation
    |
    berzosertib (M6620)
    Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors (NCT05431582)
    Phase 1
    M.D. Anderson Cancer Center
    Withdrawn
    Last update posted :
    06/15/2023
    Initiation :
    12/14/2022
    Primary completion :
    12/14/2022
    Completion :
    12/14/2022
    TP53 • CCNE1
    |
    TP53 mutation • CCNE1 amplification • TP53 amplification
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • azenosertib (ZN-c3)
    A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency (NCT02873975)
    Phase 2
    Dana-Farber Cancer Institute
    Completed
    Last update posted :
    10/21/2022
    Initiation :
    10/12/2016
    Primary completion :
    09/30/2020
    Completion :
    07/01/2021
    BRCA1 • BRCA2 • MYC • CCNE1 • FBXW7 • CHEK2 • RAD51C • RAD51D
    |
    BRCA2 mutation • BRCA1 mutation • ATM mutation • MYC amplification • PALB2 mutation • CCNE1 amplification • FBXW7 mutation • RAD51C mutation • RAD51D mutation • RAD51 mutation
    |
    prexasertib (ACR-368)